Montana-based Company Inimmune Secures $22M Investment

Wednesday, January 13 2021

Inimmune, a biotechnology company based in Missoula, Montana, has accomplished its first outside investment with $22 million in Series A funding. Inimmune participated in the ASCEND Business Advising Cohort in 2019 where executives received technology review and pitch preparation.

The investment will fund the advancement of Phase I human clinical trials for late-stage pre-clinical drug candidates in oncology and allergy. Inimmune has been working to develop immunotherapeutics and vaccines since it was founded in 2016. 

Jay Evans, PhD, CEO and President at Inimmune said the partnership with Two Bear Capital for the Series A investment will help grow a “world-class biotech company” in Montana. The company is also partnering with the University of Montana on a COVD-19 vaccine. 

To read the full article click here!

Read 4157 times Last modified on Monday, 25 October 2021 23:36